PR Newswire, Monday, February 02, 1998 at 15:36
NEEDHAM, Mass., Feb. 2 /PRNewswire/ -- UroMed Corporation (NASDAQ:URMD),
today announced the appointment of Joel B. Weinstein as the company's Vice
President of Sales and Marketing for its Assurance Medical division, which is
focused on developing proprietary products that address the challenges of
early detection of breast cancer. Mr. Weinstein comes to the company from
HOLOGIC, Inc. a manufacturer of specialty x-ray devices. At HOLOGIC, Inc., he
was most recently Vice President, Marketing/Business Development.
John G. Simon, UroMed's chairman of the board and chief executive officer,
commented, "The addition of Joel to the team is a significant achievement for
UroMed Corporation, because the position will assist with the growth and
development of the company's Assurance division. Joel is extremely talented
and understands the female healthcare diagnostic business. He is an ideal fit
with our breast care strategy. He is also familiar with growing a business
from its initial start-up phase to a successful sales level. His track record
includes building HOLOGIC, Inc.'s diagnostic business from no sales to $91
million in sales over a nine-year period. We welcome his expertise in
advancing Assurance Medical's exciting breast cancer screening technology to
market."
Alan West, Managing Director of Assurance Medical, stated, "Joel is an
energetic and creative marketer with extensive background in the breast cancer
and osteoporosis screening markets. Joel is an important addition to our
Assurance team, and we look forward to his contributions in the coming
quarters as we move our BreastCheck(TM) technology through the regulatory
process."
Weinstein stated, "The BreastCheck technology developed by Assurance
Medical and the market it addresses combine to make this the most exciting
startup division that I have had the opportunity to be associated with. My
short term priorities will be focused on the development of marketing
strategies to help develop and launch this important new approach for women in
the fight against breast cancer."
Mr Weinstein has over 15 years of successful marketing experience with
medical products including 10 years at HOLOGIC, Inc., where he was responsible
for overseeing all facets of marketing for products in the women's health area
related to the diagnosis and monitoring of osteoporosis. He also established
U.S. and international sales channels, and qualified, recruited, trained and
supported an international dealer network. He was one of the first employees
of HOLOGIC, Inc., and participated in its venture capital financing. Prior to
joining HOLOGIC, Inc., Mr Weinstein held various positions at Advanced
Technology Laboratories, a manufacturer of medical diagnostic ultrasound
apparatus, including Vice-President, Business Development and Marketing
Director. Mr. Weinstein also has extensive experience with health care
reimbursement issues. Mr. Weinstein graduated from Western New England
College with a Master of Business and from the City College of New York with a
Bachelor of Engineering. He and his family reside in Framingham, MA.
UroMed, founded in October 1990, is dedicated to establishing itself as a
leader in the development of male and female healthcare products. UroMed has
three primary areas of initial focus: breast cancer, prostate cancer and
incontinence. In the area of incontinence, UroMed offers the Reliance(R)
Urinary Control Insert and the INTROL(R) Bladder Neck Support Prosthesis --
both FDA-cleared for marketing, as well as the PelvicFlex(TM) educational
training video. In addition, this year UroMed intends to expand its FDA-
cleared continuum of continence care products by offering the Impress(TM)
Softpatch and the BEACON Technology System(TM), a minimally invasive
incontinence surgical line. In the area of breast cancer, UroMed is developing
its BreastCheck(TM) breast self examination device together with its
physician-use BreastExam(TM) counterpart device. Both devices may potentially
enhance breast cancer detection. The BreastCheck technology is an
investigational technology and must receive FDA approval prior to commercial
launch. In the area of prostate cancer UroMed has received FDA clearance for
its CaverMap Surgical Aid system. UroMed also continues to dedicate
significant resources to the development and/or acquisition of new options
that fit into UroMed's continuum of care in male and female healthcare.
NOTE: INTROL(R) Bladder Neck Support Prosthesis and Reliance(R) Urinary
Control Insert are registered trademarks of UroMed Corporation. Impress(TM)
Softpatch, PelvicFlex(TM) Personal Trainer Video, BEACON Technology
System(TM), BreastCheck(TM), BreastExam(TM), and CaverMap(TM) Surgical Aid are
trademarks of UroMed Corporation.
SOURCE UroMed Corporation
-0- 2/2/98
/CONTACT: Kristen Galfetti, Manager of Investor Relations of UroMed
Corporation, 781-433-0033 or James R. Buckley, Senior Consultant of Sharon
Merrill Associates, 617-542-5300/ |
